Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVJF) EBIAT (2016 - 2025)

Historic EBIAT for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $481.0 million.

  • Teva Pharmaceutical Industries' EBIAT rose 27490.91% to $481.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 17072.32%. This contributed to the annual value of $1.4 billion for FY2025, which is 17238.39% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EBIAT of $481.0 million as of Q4 2025, which was up 27490.91% from $434.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' EBIAT ranged from a high of $1.7 billion in Q4 2023 and a low of -$1.3 billion during Q4 2022
  • For the 5-year period, Teva Pharmaceutical Industries' EBIAT averaged around -$101.0 million, with its median value being -$44.5 million (2021).
  • Its EBIAT has fluctuated over the past 5 years, first crashed by 123690.48% in 2022, then soared by 27490.91% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' EBIAT (Quarter) stood at -$152.0 million in 2021, then tumbled by 776.97% to -$1.3 billion in 2022, then soared by 227.31% to $1.7 billion in 2023, then plummeted by 116.21% to -$275.0 million in 2024, then soared by 274.91% to $481.0 million in 2025.
  • Its last three reported values are $481.0 million in Q4 2025, $434.0 million for Q3 2025, and $283.0 million during Q2 2025.